Targeting the LINRIS‐IGF2BP2 axis may provide therapeutic benefits in CRC, as evidenced by reduced tumor proliferation in both orthotopic and patient‐derived xenograft models upon LINRIS inhibition.[152]. Here, LINC00920 is linked to neoplasm.